Patent · US Active

Laglidadg homing endonuclease cleaving the C-C chemokine receptor type-5 (CCR5) gene and uses thereof

US10006052B2 · kind B2 · utility

13Cited by
0References
14Claims
0Family size

Assignees

Inventors

Key dates

Filing dateMay 28, 2014
Grant dateJun 26, 2018
Priority date
Expiry dateMay 28, 2034

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12Y301/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Disclosed herein are compositions for inactivating the human CCR5 gene comprising engineered LAGLIDADG homing endonucleases (LHEs) and their derivatives, particularly derived from members of the \-Onul subfamily of LHE. Polynucleotides encoding such endonucleases, vectors comprising said polynucleotides, cells comprising or having been treated with such endonucleases, and therapeutic compositions deriving therefrom are also provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.